JP3209601B2 - Drug-containing substance for long-term heat evaporation and heat evaporation method of medicine using the same - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a drug-containing substance for long-term heat evaporation and a method for heat-evaporation of a drug using the same, and more particularly, to insecticide, sterilization, deodorization, aroma, etc.
A drug-containing substance for heat evaporation containing a drug alone or with a minimum necessary solvent, and heating for directly or indirectly heating the drug-containing substance to stably evaporate the drug over a long period of time. It relates to the transpiration method. Here, the term "long term" refers to a case where heating can be used for about 12 hours a day for 7 days or more (that is, for a total of about 84 hours or more intermittently or continuously).

[0002]

2. Description of the Related Art Conventionally, a method of heating and evaporating a solid, liquid or paste-like drug using a heating element has been known as a heat-evaporation preparation. It is an electric mosquito trap. The electric mosquito trap is used for insecticide or the like by placing an insecticide mat containing a drug on a heating plate that is electrically heated and evaporating the drug. A material in which a drug is held on a base material such as a fiberboard mainly composed of pulp or asbestos is used.

[0003] In this type of heat evaporation method represented by an electric mosquito trap, there is a problem in how to control the decomposition and evaporation rate of a drug component to stably evaporate the drug. Conventionally, various compounds are known as sustained-release agents for controlling the transpiration of drug components, for example, piperonyl butoxide, pyrethroid insecticides, paraffins, olive oil, oils and fats such as peanut oil and the like. It has been proposed to add a repellent such as water-added oils, diethyltoluamide or the like, or certain surfactants to release the oil slowly. On the other hand, as a method for suppressing the decomposition of the active ingredient, the blending of an antioxidant is generally known.
JP-A-121927 discloses various effective antioxidants. However, even if such measures are taken, the residual ratio of the active ingredient after use by heating is high, and a problem still remains in terms of the effective use of the active ingredient.

Further, these insecticidal mats are intended to be used for heating for a very short time of about 8 to 12 hours, and are not sufficient for long-time heating. The insecticidal mat is
At the beginning of use, the amount of drug transpiration was the highest, and thereafter the amount of drug transpiration gradually decreased, and there was a drawback that stable drug transpiration could not be obtained. In other words, conventional insecticidal mats reduce the evaporation of drug components by incorporating a large amount of a low volatilization evaporation inhibitor having a lower vapor pressure than the drug components such as surfactants and antioxidants, in addition to the drug components. In the early stage of use, the balance between the drug component and the anti-transpiration agent is maintained to some extent, but the concentration of the anti-transpiration agent increases as the drug component evaporates and disappears, resulting in a significant anti-transpiration effect. And the amount of drug transpiration has dropped sharply from the middle to late stages of use, and the residual amount of the drug has also increased, so that stable drug transpiration has not yet been obtained.

Further, pulp mats, which are mainly used as a base material for insecticidal mats, have a high ability to adsorb chemicals, and must be heated with a high-temperature heating element to evaporate the chemicals. In addition to the risk of burns by the body, some pulp mats are made of organic pulp bound with glue or the like. In such a case, these effects appear remarkably, and stable drug transpiration cannot be obtained. Further, since the pulp mat has poor thermal conductivity, it has been necessary to heat the pulp mat at a high temperature in order to obtain a sufficient amount of chemical transpiration to obtain a sufficient insecticidal effect. Therefore, it overlaps with the above-mentioned drawbacks, and the medicine is liable to be thermally degraded, which is a factor that makes it impossible to obtain stable medicine evaporation. In addition, due to poor thermal conductivity, temperature unevenness easily occurs in the pulp mat during heating,
The inability to perform uniform heating is also a factor that makes the evaporation of the drug unstable. In addition, regarding the application of the chemicals of the present invention to long-term heat evaporation, when the pulp mat is used for a long period of time, the pulp mat has an excellent ability to contain a chemical. Is possible. However, when a large amount of a drug is contained, the pulp mat has elasticity, and there is such a drawback that the drug exudes to the pulp mat surface when a physical force is applied, which is not practical.

[0006] As a measure for obtaining a long-term chemical vaporization, a part of the heated vaporized body is immersed in the chemical solution to absorb the chemical solution into the heated vaporized body, and the upper part thereof is heated to heat the vaporized body. A method to evaporate the liquid medicine
Various so-called chemical liquid absorption-type heat evaporation methods have been proposed. However, the chemical solution used in the heat evaporation method of the chemical solution absorption type is generally an organic solvent solution. For example, in the case of an insecticidal solution, n containing a fixed concentration of a pyrethroid drug is generally used.
Those made of hydrocarbon solutions such as paraffin are on the market. However, the hydrocarbon-based solvent has a disadvantage that it is very easy to burn and easily causes a fire. In recent years, the destruction of the ozone layer and air pollution on a global scale due to chlorofluorocarbons and volatile organic compounds have become a problem. And 90% or more of solvents such as hydrocarbon solvents. Therefore, reducing this solvent is an important issue. Furthermore, in the case of the chemical liquid absorption type, the internal pressure in the chemical liquid container fluctuates due to fluctuations in temperature, atmospheric pressure, and the like, causing liquid leakage, and contamination with the chemical liquid may occur during use or storage. In addition, the heat absorption and evaporation method of the chemical liquid absorption type, in order to evaporate the chemical liquid containing the solvent,
Considering the thermal efficiency, it can be said that unnecessary heat is required because not only the chemicals but also the solvent are evaporated. Furthermore, in the heat absorption and evaporation method of the chemical liquid absorption type, immediately after use,
It has a drawback that the amount of drug evaporated is not stable.

Accordingly, an object of the present invention is to solve the above-mentioned problems, to minimize the use of solvents,
Alternatively, it contains a high-concentration drug component containing a minimum amount of solvent, hardly causes clogging when used under heating, and is a stable quality new heat evaporation that can effectively evaporate a sufficient drug for a long period of time. The object of the present invention is to provide a drug-containing body. Furthermore, an object of the present invention is to directly or indirectly heat a drug-containing substance coated with and impregnated with a drug during heating and evaporation of the drug, thereby suppressing thermal decomposition of the drug and deterioration such as clogging of the drug-containing substance, It is an object of the present invention to provide a method which is excellent in an effective volatilization rate and can stably evaporate a drug for a long period from the initial use.

[0008]

According to the present invention, in order to achieve the above object, calcium hydrogen phosphate and its anhydride, calcium phosphate and its anhydride, and hydroxyapatite (apatite) are selected. The drug component is preferably added to the solid porous material based on calcium phosphates, preferably as it is or 100 parts by weight of the drug component.
A long-term heat-transpiration drug-containing substance is provided which is contained together with a solvent in a proportion of 0 parts by weight or less . Further, according to the present invention, there is provided a method of heating and evaporating a medicine, wherein the surface of the heat-evaporating medicine-containing body is heated to a temperature of 50 to 150 ° C by a direct or indirect heating method.

[0009]

The present inventors have conducted intensive studies to develop a drug-containing substance capable of evaporating only a drug component by heating for a long period of time, and as a result, based on calcium phosphates such as calcium phosphate, The present inventors have found that the object can be achieved by using a solid drug-containing substance containing only a drug component or a minimum necessary amount of a solvent, thereby completing the present invention. That is, the drug-containing substance for long-term heat evaporation of the present invention is based on the calcium phosphates described above, and the drug component is added as it is or dissolved in a minimum necessary solvent, and applied by an appropriate method such as coating or dipping. It is a solid drug-containing substance contained therein, which is directly or indirectly heated by a heating element or the like to evaporate the drug. At this time, calcium phosphates used as a base material have good chemical resistance and heat resistance, so that their physical properties do not change during heating use, do not deteriorate even after long-term heating use, and cause clogging. Without this, it is possible to heat and evaporate the medicine for a long period of time. Therefore, by using the heat-evaporation drug-containing substance of the present invention, the drug component can be contained at a high concentration, can be heated indirectly and directly, and in any case, a high effective volatilization rate Thus, the drug can be stably evaporated over a long period of time. Hereinafter, the operation of the present invention will be described in more detail.

The drug-containing substance of the present invention uses calcium phosphates as a base material. Calcium phosphates are particularly excellent in drug stability, and can stably evaporate a drug over a long period of time without causing thermal degradation of the drug when used under heating. In addition, since the content of the drug is excellent, the drug can be contained in a large amount. During storage, the drug does not exude to the surface of the contained body even if a physical force is applied, and the content is always kept stable. In addition, when used under heating, the drug is not easily adsorbed, so that the drug is easily released, and after long-time heating, the remaining amount of the drug is reduced, so that most of the contained drug can be evaporated. That is, by directly or indirectly heating the solid drug-containing substance of the present invention to evaporate the drug, the drug evaporates mainly from the heated portion of the drug-containing substance, and accordingly, the drug becomes the drug-containing substance. From the portion other than the heated side to the heated side portion, that is, from the high concentration region of the drug to the low concentration region, but the calcium phosphates as the base material has poor adsorption ability of the drug, so the drug The transpiration of the medicine is supplied without excess or shortage, and it is not as short as about 8 hours as in the conventional insecticidal mat,
It is possible to evaporate the drug stably over a long period of time, and it is possible to evaporate almost all the drug contained during long-term use.

The drug-containing substance of the present invention based on calcium phosphates has excellent thermal conductivity as compared with pulp mat, and further contains only a drug component or a minimum necessary solvent. In order to evaporate the drug at a high concentration, it is possible to evaporate the drug at a lower temperature. Therefore, while being able to further ensure the stability of the drug to heat,
Since the drug-containing substance is uniformly heated, stable drug evaporation can be obtained without causing temperature unevenness in the drug-containing substance.
In addition, in the case of low-temperature use, it is possible to avoid the danger of burns due to a heating element due to misuse, thereby improving safety. Further, since the heater is used at a low temperature, the power consumption of the heating element is small and energy can be saved. For example, a small-capacity power source such as a dry battery can be used.

Further, according to the drug-containing substance for heat evaporation and the method of heating and evaporating a drug using the same according to the present invention, a high-concentration drug containing only a drug component or a minimum amount of solvent is evaporated. The thermal efficiency is better than the above-mentioned heat absorption and evaporation method of the chemical liquid absorption type. That is, in the heat absorption and evaporation method of the chemical liquid absorption type, since not only the evaporation of the drug but also the evaporation of the solvent is required, unnecessary heat is used, and the time required to reach the evaporation amount to obtain the desired effect is obtained. It costs. In contrast, the drug-containing substance of the present invention requires only heat to evaporate the drug, and therefore has a very good thermal efficiency. Therefore, it is possible to evaporate the medicine with a smaller amount of heat than the liquid absorption type, and as a result, it is possible to reduce the power consumption of the heating element and to save energy, and to quickly contain the medicine immediately after energizing the heating element. The body is heated, and the rise of the drug transpiration becomes very good. For example, in the case of an insecticide, a stable insecticidal effect can be obtained from the beginning of use.

Further, the heat evaporation method of the present invention is different from the conventional heat absorption and evaporation method of absorbing a chemical solution, because it does not basically use an organic solvent solution of a drug, and therefore does not require a chemical solution container and causes liquid leakage. Without, a very compact design is possible, and the drug can be evaporated just by heating the solid drug-containing substance containing the drug,
The risk of fire can be avoided and safety can be improved. Also,
The heat-evaporating drug-containing substance of the present invention uses only the drug component or the minimum necessary amount even when a solvent is used, so that it is possible to significantly reduce the adverse effect on the atmosphere by evaporating the solvent. Become.

[0014]

DETAILED DESCRIPTION OF THE INVENTION The agent-containing substance for heat evaporation according to the present invention is based on calcium phosphates such as calcium hydrogen phosphate and its anhydride, calcium phosphate and its anhydride, and apatite calcium such as hydroxyapatite. Mixed with other inorganic and / or organic powders and additives as needed,
It is prepared by a method such as compression molding and extrusion molding. Here, inorganic and / or organic powders that can be blended as needed include magnesium aluminate metasilicate, hydrotalside, aluminum hydroxide gel, aluminum magnesium magnesium, calcium carbonate, aluminum silicate, magnesium silicate, anhydrous silica Inorganic powders such as acid, clay, diatomaceous earth, kaolin, colloidal silica, water glass, aluminum phosphate, magnesium phosphate, gypsum, magnesia cement, tungsten, tungsten trioxide, wax, aluminum oxide, titanium dioxide,
Fluorine-based resins such as PTFE (tetrafluoroethylene resin) and PVdF (vinylidene fluoride resin), polyacetal,
Polyarylate, polyetheretherketone, polyethylene, polyethylene terephthalate, polycarbonate
Polyamide, polyimide, polyamide imide, polysulfone such as nylon 6, nylon 66, nylon 11, nylon 12, aromatic nylon and copolymers thereof.
Polysulfone resins such as polyethersulfone, polyphenylene ether, polyphenylene sulfide, polybutylene terephthalate, polypropylene, polymethylpentene, AES resin, AS resin, ABS resin, MBS
Thermoplastic resin powder such as resin, crystalline cellulose, CMC,
Organic powders such as MC, starch, HPMC, HPC, and HPS are exemplified. When the above-mentioned thermoplastic resin powder is used, the strength of the drug-containing substance can be improved by molding the drug-containing substance and then heat-fusing the powder near the melting point of the thermoplastic resin powder.

The heat-evaporating drug-containing material of the present invention is porous, and its porosity is usually 15 to 60%, preferably 20 to 50%, so that a stable evaporative effect over a long period of time can be obtained. Can be achieved. That is, when the porosity is less than 15%, the transfer of the drug in the heating-evaporation drug-containing body is not performed smoothly. Therefore, the evaporation of the drug in the heated portion of the drug-containing material and the supply of the drug to the heated portion are not performed. It is not preferable because the balance is poor and stable evaporation of the drug is difficult to obtain. On the other hand, 6
A porosity of 0% or more is not preferred because thermal conductivity becomes poor and it becomes difficult to evaporate the drug at low temperatures. In addition, the shape of the heat-evaporating drug-containing substance of the present invention is arbitrary, such as a flat plate, a donut, and a column, and is selected according to the shape of the heating portion of the heating element and the evaporability of the drug.

The heat-evaporating drug-containing material of the present invention also contains powder having fluidity and lubricity during compression molding and extrusion molding.
In order to improve the lubricity, if necessary as a lubricant within the range that does not impair the properties of the heat-evaporating drug-containing body, as a lubricant,
Talc, stearates such as magnesium stearate and sodium stearate, amino acid-based lubricants such as N-lauryl-DL-aspartic acid-β-lauryl ester and N ⁶ -lauroyl-L-lysine, boric acid, and liquid paraffin And waxes such as sodium benzoate and carbowax, crystalline cellulose and the like can also be added. Further, a fibrous powder such as glass fiber or carbon fiber may be added to improve the strength of the heat-evaporating drug-containing substance.

If necessary, pigments, pigments, preservatives, antioxidants, ultraviolet absorbers, flame retardants, accidental corrosion inhibitors, etc. may be added to the heat-evaporating agent-containing substance as long as the properties are not impaired. You may mix | blend an agent. As the antioxidant that can be added, it is preferable to use an antioxidant that does not decompose or evaporate during heating and is added to a normal polymer resin. For example, stearyl-β- (3,5-di-t-butyl-4-hydroxyphenyl) propionate, 2,2′-methylenebis (4
-Methyl-6-t-butylphenol), 2,2'-methylenebis (4-ethyl-6-t-butylphenol), 4,4'-methylenebis (2,6-di-t-butylphenol), 4,4 ' -Butylidenebis (3-methyl-6-t-butylphenol), 4,4′-thiobis (3-methyl-6-t-butylphenol), 1,3
5-trimethyl-2,4,6-tris (3,5-di-t
-Butyl-4-hydroxybenzyl) benzene, 1,
1,3-tris- (2-methyl-4-hydroxy-5-
t-butylphenyl) butane, tetrakis- [methylene-3- (3 ′, 5′-di-tert-butyl-4′-hydroxyphenyl) propionate] methane, 2-mercaptobenzimidazole, 1,1-bis (4 -Hydroxyphenyl) cyclohexane, N-phenyl-β-naphthylamine, N, N′-diphenyl-p-phenylenediamine, 2,2,4-trimethyl-1,2-dihydroquinoline polymer, 6-ethoxy-2,2, 4-trimethyl-
1,2-dihydroquinoline, 2-t-butyl-6- (3
-T-butyl-2-hydroxy-5-methylbenzyl)
-4-methylphenyl acrylate, 3,5-di-t-
Butyl-4-hydroxy-benzylphosphonate-
Diethyl ester, bis (3,5-di-t-butyl-4)
-Ethyl ethyl hydroxybenzylphosphonate) calcium,
Tris [2- (3 ′, 5′-di-tert-butyl-4′-hydroxyhydro-cinnamoyloxyl) ethyl] isocyanurate, tris- (4-tert-butyl-2,6-di-methyl-3) -Hydroxybenzyl) isocyanurate, 3,9-bis [1,1-di-methyl-2- {β-
(3-t-butyl-4-hydroxy-5-methylphenyl) propionyloxydiethyl] -2,4,8,10
-Tetraoxaspiro [5.5] undecane, ditridecyl-3,3'-thiodipropionate, dimyristyl-3,3'-thiodipropionate, distearyl-
3,3'-thiodipropionate, triethylene glycol-bis [3- (3-t-butyl-5-methyl-4-
Hydroxyphenyl) propionate], 1,6-hexanediol-bis [3- (3,5-di-t-butyl-
4-hydroxyphenyl) propionate], N, N '
-Hexamethylenebis (3,5-di-t-butyl-4-
Hydroxy-hydrocinnamamide), 2,2-thio-diethylenebis [3- (3,5-di-tert-butyl-4-hydroxyphenyl) propionate], N, N'-bis [3- (3 5-di-t-butyl-4-hydroxyphenyl) propionyl] hydrazine, tris- (3,5-
Di-tert-butyl-4-hydroxybenzyl) -isocyanurate, 2,4-bis- (n-octylthio) -6
(4-hydroxy-3,5-di-t-butylanilino)
And compounds such as -1,3,5-triazine.
These compounds may be used alone or in combination of two or more.

When the drug is contained in the heat-evaporating drug-containing substance, a minimum necessary solvent may be used for the purpose of improving the permeability and diffusion of the drug into the drug-containing substance. As the solvent, for example, aliphatic saturated hydrocarbon and unsaturated aliphatic hydrocarbon solvents can be used. In addition, water, alcohols, glycol ethers such as ethylene glycol monobutyl ether and the like, and glycols, and esters such as isopropyl myristate and butyl stearate can also be used. In this case, the amount of the solvent used is preferably 10 parts by weight or less based on 100 parts by weight of the drug.

The heat-evaporation drug-containing body of the present invention comprises an insecticide,
For the purpose of sterilization, deodorization, aroma, and the like, it can be suitably used as a heat-evaporation drug-containing substance of a heat-evaporation device for heat-evaporation of various insecticides, disinfectants, deodorants, and fragrances. FIG. 1 shows an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention. In the figure, reference numeral 1 denotes a heating-evaporation drug-containing body according to the present invention, which is used by being placed on a heating element 3 of a heating device 2. FIG. 2 shows another embodiment of the heat-evaporation drug-containing material. This drug-containing substance for heat evaporation comprises a drug-containing substance 1 and a container 4 containing the same. The container 4 further includes two members, an upper container 5 and a lower container 6, and a plurality of ribs 7 for supporting the drug-containing substance on its inner surface.
Are formed. Further, ventilation holes 8 and 9 are formed in the center portions of the upper container 5 and the lower container 6, respectively. A projection 10 is formed on the outer surfaces of the upper container 5 and the lower container 6 so that a gap is formed between the container 4 and the heating element when the container is placed on the heating element, and the space is heated indirectly. Has been established. Note that, without forming the protruding portion 10, the container 4 may be directly placed on the heating element and may be indirectly heated via the bottom wall of the lower container 6. The ribs 7 are provided between the inner surfaces of the upper container 5 and the lower container 6 and the medicine-containing body 1.
As a result, a gap X is formed, and the medicine evaporated by heating flows more smoothly toward the opening 11. Although what is shown above is an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention, it is needless to say that apparatuses of various shapes can be used without being limited thereto. Alternatively, a configuration may be adopted in which a heat conductive member is provided on the heating element, and the drug-containing body is heated by the heat conducted to the heat conductive member.

It is desired that the material for the container holding the drug-containing material has heat resistance and chemical resistance according to the drug used. For example, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, polyacetal, melamine resin, polytetrafluoroethylene, phenolic resin, unsaturated polyester resin, epoxy resin, urethane resin, methacrylic acid resin, polyarylate, Examples thereof include polyketone, polyamideimide, polyallyl sulfone, polyphenylene sulfide, polyphenyl sulfone, and polyether nitrile. The shape of the container is selected according to the shape of the drug-containing substance for heat evaporation. Also figure
A container may not be used as in the usage mode shown in FIG.

The heating temperature at the time of using the heating is as follows:
Although it is selected according to the medicine to be contained, it is usually preferable to keep the surface temperature of the heated portion of the heat-evaporation medicine-containing body at 50 ° C to 150 ° C, regardless of whether a container is used or not. More preferably, the temperature is 70 ° C to 120 ° C. The heating method is direct heating or indirect heating depending on the heating element used. Examples of the heat generating method of the heating element include a method of energizing a heater using a resistance heater (such as a nichrome wire) and a semiconductor (PTC), an oxidation reaction (oxidation of a metal such as iron and magnesium), and a hydrolysis reaction (quick lime). Reaction with water, etc.), a method of using combustion heat of alcohol, gas, kerosene, wax, etc., a method of using combustion heat of alcohol, gas, etc. using a platinum catalyst, and a method of directly or indirectly using other heat sources. Is used.

The heat-evaporating drug-containing substance of the present invention can contain various heat-evaporable drugs depending on the purpose of use. For example, when used for the purpose of insecticide, as the insecticide, various heat-evaporating insecticides conventionally used can be used, and examples include a pyrethroid-based insecticide, a carbamate-based insecticide, and an organic phosphorus-based insecticide. be able to. In general, pyrethroid insecticides are preferably used because of their high safety. For example, allethrin (hereinafter referred to as AB-
1), d1.d-T80-aresulin (hereinafter, abbreviated as AB-2), d.d-T80-aresulin (hereinafter, abbreviated as AB-3), d.d-T80-praletrin ( Hereinafter, AB-4), phthalthrin (hereinafter, abbreviated as AB-5), d-T80-resmethrin (hereinafter, abbreviated as AB-6), d-T80-framethrin (hereinafter, AB-7) Abbreviated), permethrin (hereinafter abbreviated as AB-8), phenothrin (hereinafter abbreviated as AB-9), fenvalerate (hereinafter abbreviated as AB-9)
AB-10), cypermethrin (hereinafter AB)
-11), cyphenothrin (hereinafter AB-1)
2), empentrin (hereinafter abbreviated as AB-13), terrareslin (hereinafter abbreviated as AB-14), etofenprox (hereinafter abbreviated as AB-15), benfluthulin (hereinafter abbreviated as AB- 16) can be used. Similarly, when used for the purpose of fragrance, various natural and artificial flavors can be used,
For example, animal and vegetable natural flavors, hydrocarbons, artificial fragrances such as alcohols, phenols, aldehydes, ketones, lactones, oxides, esters and the like.
The seeds can be used alone, or two or more can be used as a mixture. Furthermore, depending on the purpose, deodorant, bactericide,
Various chemicals such as anti-binders, rust preventives, acaricides, repellents and the like can be used as long as they evaporate by heating.
The content of the drug is 1 to 30 per 100 parts by weight of the drug-containing substance.
It is preferable to include the parts by weight. Also, the drug to be evaporated may be added by a suitable method such as dripping, coating, and dipping after forming the drug-containing body as described above, or the drug may be impregnated into a base material before forming the drug-containing body, and thereafter, The drug-containing substance may be formed.

[0023]

The present invention will be specifically described below with reference to examples and comparative examples.

Examples 1 to 4 The powders shown in Table 1 below were mixed, and 200 kg
/ Cm ² to obtain a flat solid drug-containing substance (18 × 30 × 2.5 mm, weight 3 g). In addition, crystalline cellulose (trade name: Avicel, manufactured by Asahi Kasei Kogyo Co., Ltd.) in the powder is generally used as a compressibility improver.

[Table 1]

Comparative Example 1 A commercial pulp mat (18 × 30 × 2.
5 mm).

Test Example 1 (Measurement of Surface Temperature of Drug-Containing Body) The drug-containing bodies manufactured in Examples 1 to 4 and the commercially available pulp mat of Comparative Example 1 were set in a heating evaporator shown in FIG. Energize the heating element to reduce the surface temperature at the top center of the heating element to 1
Heating was performed at 30 ° C ± 5 ° C, 150 ° C ± 5 ° C, and 170 ° C ± 5 ° C. One hour after the start of energization, the temperature distribution of the drug-containing material and the upper surface of the pulp mat was examined with a thermocouple type surface thermometer. In addition, as shown in FIG. 3, the temperature measuring section is about 5 m from the center and both ends on a diagonal line of 18 × 30 mm.
The measurement was performed under the condition of room temperature 25 ° C. with three points in total at m points. Table 2 shows the results.

[Table 2]

As is evident from the results shown in Table 2, the drug-containing substance of the present invention using calcium phosphates as a base material has good thermal conductivity. As compared with the commercial pulp mat of Comparative Example 1, the surface temperature of the drug-containing material was generally higher, and the temperature differences between the respective parts were small and almost uniform. In the case of Comparative Example 1,
The temperature at the center of the drug-containing body located at the center of the heating element tends to be the highest, and the temperature at the ends tends to be low. This indicates that temperature unevenness occurs on the heated drug-containing body. As described above, the temperature of the drug-containing body of the drug-containing body of the present invention is higher than that of a conventional pulp mat even with a low-temperature heating element, and the drug can be evaporated. In addition, since the temperature of the drug-containing body is extremely small and is uniformly heated, stable drug evaporation can be obtained.

Examples 5 to 8 The components having the formulations shown in Table 3 below were mixed, compression-molded with a press machine at a pressing pressure of 200 kg / cm ² , and a drug-containing substance (18 × 30 × 3.5 mm, weight 3g) was prepared. The nylon 12 in the powder was used for the purpose of improving the compressibility and strength of the drug-containing substance.

[Table 3]

Comparative Example 2 For comparison, a commercial pulp mat (18 × 30 × 2.5)
mm).

Test Example 2 (Evaporation Test) The solid drug-containing materials produced in Examples 5 to 8 and the commercial pulp mat of Comparative Example 2 were impregnated with a predetermined amount of each of the agents shown in Table 4 by immersion. The sample was set in the heating evaporator shown in FIG. Energize the heating element to reduce the surface temperature of the heating element to 120
The solution was heated to a temperature of 5 ° C. ± 5 ° C., and the amount of drug evaporated at each heating time was measured. Table 5 shows the results. In addition, the amount of transpiration was measured as follows. Evaporation amount: After evaporating drug is trapped at regular intervals for 1 hour in a silica gel packed column, extracted with acetone, concentrated,
Quantitative analysis was performed by gas chromatography.

[Table 4]

[0031]

[Table 5]

As is evident from the results shown in Table 5, Comparative Example 2 and Examples 5 to 8 all have the same heated area and are heated by the same temperature heating element. In the case of No. 2, the calorific value is insufficient, and a sufficient amount of chemical transpiration has not been obtained. In addition, the amount of drug transpiration has been gradually reduced over time. In comparison, the drug-containing substance comprising calcium phosphates of the present invention provided a sufficient amount of drug transpiration and a stable amount of drug transpiration over 84 hours.

Test Example 3 (Efficacy Test) Each of the drugs shown in Table 4 was impregnated with a predetermined amount of each of the drugs shown in Table 4 in the drug-containing bodies produced in Examples 5 and 6, and each was set in the heating evaporator shown in FIG. . 12 hours of use per day, equivalent to the first day of energization of the heating element (no energization before test), equivalent to 3 days of energization (24 hours before energization before test), equivalent to 7 days of energization (72 hours before energization before test) The knockdown effect on the adult female Culex pipiens was examined for the inclusions. The energization before the test was repeated energization for 12 hours and non-energization for 12 hours, and the upper surface of the heating element was heated to 120 ° C. ± 5 ° C. The sample, which had been energized for a predetermined time before the test, was placed in the center of the lower surface of an 8-tatami room, and three adults of Culex pipiens were released three hours after the start of energization, and the number of knockdown insects over time was confirmed. And the time for 50% to fall and turn (KT-50)
Was measured. Table 6 shows the results.

[Table 6]

As is evident from the results shown in Table 6, the drug substance comprising calcium phosphates of the present invention contained 1
It can be seen that a stable insecticidal effect was always obtained from day 7 to day 7.

[0035]

As described above, the present invention is based on a calcium phosphate as a base material, mixed with other inorganic and / or organic powders and additives as required, and then subjected to compression molding, extrusion molding, etc. Formed by the method, using the drug component for heating and evaporation containing only the drug component or the minimum necessary solvent with the drug component, because it is directly or indirectly heated to perform drug evaporation, The following effects and advantages can be obtained. B) Since calcium phosphates having good thermal conductivity are used as a base material, a sufficient amount of drug can be obtained by heating at a relatively low temperature so that the desired effect can be obtained. Effective and stable drug evaporation is obtained. B) The use of minimal or no solvents is required, avoiding the danger of fire, improving safety, and significantly reducing volatile organic compounds. The adverse effects can be reduced. The advantage of resource saving is also obtained. C) Since only the drug component is evaporated, the thermal efficiency is good, the drug evaporation is stable, and in the case of an insecticide, a stable insecticidal effect can be obtained after electricity is supplied to the heating element. In addition, the power consumption of the heating element is small, energy can be saved, and for example, a small-capacity power supply such as a dry battery can be used.
The heating device can be made compact and portable. D) Since the chemicals are evaporated using a low-temperature heating element, the risk of burns can be avoided and safety can be improved. E) Since the drug is evaporated using only the drug or a solid drug-containing substance that is contained together with the minimum necessary solvent, a drug solution container is not required unlike the conventional drug solution absorption type. Therefore, there is no problem such as liquid leakage, and a very compact design can be achieved, and resource saving and cost reduction can be achieved.

[Brief description of the drawings]

FIG. 1 is a schematic cross-sectional view showing an example of an apparatus suitable for using the drug-containing substance for heat evaporation according to the present invention, omitting an internal structure of the heating apparatus.

FIG. 2 is a cross-sectional view showing another use mode of the heat-evaporation drug-containing body of the present invention.

FIG. 3 is a plan view showing a temperature measurement site of a drug-containing substance used in Test Example 1.

[Explanation of symbols]

 1 Drug-containing substance for heat evaporation 2 Heating device 3 Heating element

──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int.Cl. ⁷ , DB name) A01N 25/18 103 A01N 25/18 101 A01N 25/08

Claims (3)

(57) [Claims] 1. Calcium hydrogen phosphate and its anhydride,
For long-term heat evaporation, characterized by containing a heat-evaporable drug component in a solid porous body based on at least one or more inorganic powders selected from calcium phosphate and anhydrides thereof, and hydroxyapatite. Drug substance. 2. The heat-evaporable drug component is added in a weight of 10 parts without using a solvent or 100 parts by weight of the drug component.
The drug-containing substance for long-term heat evaporation according to claim 1, wherein the substance is contained together with a solvent in an amount of not more than part by weight . 3. Calcium hydrogen phosphate and its anhydride,
Calcium phosphate and its anhydride, and a solid porous body based on at least one or more of inorganic powders selected from hydroxyapatite, heat-evaporable drug component without using a solvent or 100 parts by weight of drug component Against
A method of heating and evaporating a drug, comprising heating the surface of the heat-evaporating drug-containing body, which is contained together with a solvent in a proportion of 10 parts by weight or less, at 50 to 150 ° C. to evaporate the drug.